| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $15.0M | -26.2% | -9.4% |
| SG&A Expense | $4.1M | -8.0% | +2.8% |
| Operating Income | -$19.1M | +22.9% | +7.0% |
| Net Income | -$17.5M | -55.7% | -122.7% |
| EPS (Basic) | -$0.21 | -61.5% | -120.0% |
| EPS (Diluted) | -$0.21 | -61.5% | +34.4% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.7M | -36.1% | -45.7% |
| Short-term Investments | $89.7M | -11.9% | +25.6% |
| Current Assets | $96.3M | -13.6% | +18.1% |
| Total Assets | $129.9M | -10.4% | +13.3% |
| Current Liabilities | $14.3M | +4.2% | +14.5% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$48.3M | — | — |
| Investing Cash Flow | $31.3M | — | — |
| Financing Cash Flow | $115K | — | — |
| $38.8M |
| -0.2% |
| +0.7% |
| Stockholders' Equity | $35.4M | -29.7% | -53.5% |